A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist, is used to treat obesity in adults, but assessment of the drug in adolescents has been lacking. I ...

The US Food and Drug Administration issued a warning Tuesday about compounded versions of the drug semaglutide, which is approved for treatment of diabetes and excess weight. Compounding “is the ...

The phase 3a STEP 1 trial that investigated the use of semaglutide (Novo Nordisk), a glucagon-like peptide-1 (GLP-1) agonist, for weight loss is aptly named, some say. "In sum, we have a long way ...

At week 104, among patients receiving semaglutide, the mean body weight decreased from 92.1 kg at baseline to 88.5 kg in the group receiving 0.5 mg and to 87.2 kg in the group receiving 1.0 mg ...

The STEP program focused on semaglutide's efficacy in weight loss for individuals with and without type 2 diabetes. 9 These trials demonstrated significant weight loss with semaglutide compared to ...